Search

Your search keyword '"Lidia Calabrese"' showing total 2 results
Start Over Author "Lidia Calabrese" Topic humans
2 results on '"Lidia Calabrese"'

1. Quantitative description of <scp>SARS‐CoV</scp> ‐2 <scp>RT‐PCR</scp> , a cohort of 76 <scp>COVID</scp> ‐19 older hospitalized adults

Author

Anita Meyer, Patrick Karcher, Louise F. Porter, Erik Sauleau, Antonin Michaud, Samira Fafi-Kremer, Thomas Vogel, Georges Kaltenbach, Maxence Meyer, Amandine Leitner, Saïd Chayer, Aurélie Velay, Manon Leitner, Alexandre Boussuge, Marion Muller, Frédéric Blanc, Florentin Constancias, Lidia Calabrese, Elise Schmitt, Les Hôpitaux Universitaires de Strasbourg (HUS), Ortenau Klinikum Offenburg-Kehl [Offenburg, Germany], Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] (ETH Zürich), CHU Strasbourg, Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), LabEx Transplantex [Strasbourg], Université de Strasbourg (UNISTRA), Fédération Hospitalo-Universitaire (OMICARE), Centre de Recherche d’Immunologie et d’Hématologie [Strasbourg], Fédération de Médecine Translationnelle de Strasbourg (FMTS), and univOAK, Archive ouverte

Subjects
Male, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID‐19‐Related Content, Humans, Medicine, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Statistics & numerical data, Letters to the Editor, Letter to the Editor, Aged, 80 and over, SARS-CoV-2, business.industry, Research, COVID-19, Virology, Hospitalization, Real-time polymerase chain reaction, COVID-19 Nucleic Acid Testing, Cohort, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Female, France, Geriatrics and Gerontology, business
Abstract

PMCID: PMC8250917; No abstract available

Published
2021
Full Text
View/download PDF

2. Therapeutic prevention of COVID-19 in elderly: a case-control study

Author

Alexia Matzinger, Nadjiba Bougaa, Georges Kaltenbach, Elise Schmitt, Candice Muller, Catherine Jehl, Patrick Karcher, Erik Sauleau, Alexandre Boussuge, Cedric Waechter, Samira Fafi-Kremer, Thomas Vogel, Denata Mutelica, François Weill, Frédéric Blanc, Catherine Demuynck, Catherine Martin Hunyadi, Lidia Calabrese, Maxence Meyer, Carmen Suna, Delphine Gallo Imperiale, Benoit Schorr, Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie (ICube), École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Université de Strasbourg (UNISTRA)-Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), CHU Strasbourg, and univOAK, Archive ouverte

Subjects
Aging, medicine.medical_specialty, Proton pump inhibitors, Lower risk, Elderly, Internal medicine, Diabetes mellitus, medicine, Humans, Antipsychotics, Prospective Studies, Prospective cohort study, Aged, Retrospective Studies, Geriatrics, business.industry, SARS-CoV-2, Mortality rate, Prevention, Case-control study, COVID-19, Odds ratio, medicine.disease, Metformin, Clinical trial, Treatment Outcome, [INFO.INFO-TI] Computer Science [cs]/Image Processing [eess.IV], [INFO.INFO-TI]Computer Science [cs]/Image Processing [eess.IV], Case-Control Studies, Original Article, Geriatrics and Gerontology, business
Abstract

COVID-19 is a particularly aggressive disease for the elderly as 86% of deaths related to COVID-19 occur in people over 65 years of age. Despite the urgent need for a preventive treatment, there are currently no serious leads, other than the vaccination. The aim of this retrospective case-control study is to find a pharmacological preventive treatment of COVID-19 in elderly patients. One-hundred-seventy-nine patients had been in contact with other COVID-19 patients at home or in hospital, of whom 89 had tested RT-PCR-positive (COVID-pos) for the virus and 90 had tested RT-PCR-negative (COVID-neg). Treatments within 15 days prior to RT-PCR (including antihypertensive drugs, antipsychotics, antibiotics, nonsteroidal anti-inflammatory drugs, proton pump inhibitors (PPIs), oral antidiabetics (OADs), corticosteroids, immunosuppressants), comorbidities, symptoms, laboratory values, and clinical outcome were all collected. COVID-pos patients more frequently had a history of diabetes (P = .016) and alcoholism (P = .023), a lower leukocyte count (P = .014) and a higher mortality rate — 29.2% versus 14.4% — (P = .014) when compared to COVID-neg patients. Patients on PPIs were 2.3 times less likely (odds ratio [OR] = 0.4381, 95% confidence interval [CI] [0.2331, 0.8175], P = .0053) to develop COVID-19 infection, compared to those not on PPIs. No other treatment decreased or increased this risk. COVID-pos patients on antipsychotics (P = .0013) and OADs (P = .0153), particularly metformin (P = .0237), were less likely to die. Thus, patients on treatment with PPI were less likely to develop COVID-19 infection, and those on antipsychotics or metformin had a lower risk of mortality. However, prospective studies, including clinical trials, are needed to confirm or not these findings. Supplementary Information The online version contains supplementary material available at 10.1007/s11357-021-00397-z.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results